Lazard Asset Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$433M |
| 2 |
Merck
MRK
|
+$286M |
| 3 |
Jacobs Solutions
J
|
+$265M |
| 4 |
Equifax
EFX
|
+$253M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$710M |
| 2 |
Johnson & Johnson
JNJ
|
+$574M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$480M |
| 4 |
Marvell Technology
MRVL
|
+$377M |
| 5 |
Wells Fargo
WFC
|
+$333M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.04% |
| 2 | Financials | 14.64% |
| 3 | Healthcare | 12% |
| 4 | Industrials | 10.54% |
| 5 | Consumer Discretionary | 9.81% |
Similar funds
Lazard Asset Management's Q4 2024 Portfolio in Review
As of Q4 2024, Lazard Asset Management held 2,605 positions worth $68.4B, down 8.6% from $74.8B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Lazard Asset Management withdrew a net $9.95B in Q4 2024, closing 234 positions and reducing 894 holdings. Its most notable exit was Atlantica Sustainable Infrastructure plc Ordinary Shares, an estimated $210M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Lazard Asset Management opened a new position in Vaxcyte worth $39.8M.
- Lazard Asset Management's largest Q4 2024 buy was Vaxcyte: 486,764 shares worth $39.8M.
- Lazard Asset Management added most to Eli Lilly in Q4 2024, an estimated $433M increase.
- Lazard Asset Management's biggest Q4 2024 reduction was Microsoft, cutting an estimated $710M.
- Lazard Asset Management fully exited Atlantica Sustainable Infrastructure plc Ordinary Shares in Q4 2024, selling an estimated $210M.
- Lazard Asset Management's ten largest holdings make up 26% of its $68.4B portfolio in Q4 2024.
- Lazard Asset Management opened 281 new positions and closed 234 in Q4 2024.
- Lazard Asset Management's portfolio value fell 8.6% quarter-over-quarter to $68.4B.
Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.